Tag: Fcrn inhibitor

According to research published in the journal *mAbs*, nipocalimab is a fully human monoclonal antibody designed to bind with high affinity to and block the neonatal Fc receptor (FcRn). By doing so, it offers a novel approach to treating autoimmune diseases by reducing the levels of pathogenic immunoglobulin G (IgG) antibodies.

According to clinical trial data, the most common adverse reactions reported in at least 10% of patients treated with nipocalimab breakthrough therapy designation BTD were respiratory tract infection, peripheral edema, and muscle spasms. This FcRn inhibitor is under evaluation for several autoimmune and alloimmune conditions, making a review of its safety profile essential.

Over the last few years, the treatment landscape for myasthenia gravis (MG) has been revolutionized with the arrival of new, targeted therapies, moving beyond broad immunosuppression. A major development includes the approval of several new medications that specifically target key immune pathways, providing more effective and precise treatment options for patients asking, 'What is the new medicine for myasthenia gravis?'.

In 2025, the U.S. Food and Drug Administration (FDA) approved a significant new infusion for generalized myasthenia gravis (gMG), prompting many to ask what is the new pill for myasthenia gravis. While no new oral pill has been recently approved, recent advancements have focused on more targeted therapies delivered via injection or infusion that offer new hope for managing symptoms.

Founded in 2008, argenx is a global immunology company with a primary focus on improving the lives of people living with severe autoimmune diseases by translating immunology breakthroughs into a portfolio of innovative antibody-based medicines. The key question, "What does argenx do?", is answered through its strategic focus on targeting the underlying biology of these conditions with its proprietary technology platforms.

Affecting approximately 300 million people worldwide, rare diseases present an immense unmet medical need that pharmaceutical companies like Johnson & Johnson (J&J) are working to address. At the heart of J&J's strategy for autoantibody-mediated rare diseases is its FcRn inhibitor, nipocalimab, now known by the brand name Imaavy, which received FDA approval for myasthenia gravis in 2025.